Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition

Novo Nordisk A/S NVO has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability of alternative options. 

This move will lead to supply disruptions starting in mid-January, followed by discontinuation of the Levemir injection pen in April next year and Levemir vials by the end of 2024.

This decision follows Novo's commitment eight months ago to cut U.S. list prices for several insulin products, including a substantial reduction in the list price of Levemir. 

Related: Novo Nordisk Follows Eli Lilly In Slashing Insulin Prices By 75%.

Citing the company, Reuters noted global manufacturing constraints, formulary losses impacting patient access effective in January 2024, and the availability of alternative options in the U.S. market as key factors.

Basal insulin, like Levemir, is a long-acting insulin injected once or twice a day, commonly used by individuals with Type 1 diabetes and sometimes by those with Type 2.

Novo Nordisk's other long-acting insulin, Tresiba, remains on the market.

In September, Novo Nordisk announced a new partnership with Aspen Pharmacare to establish human insulin production in South Africa.

Price Action: NVO shares are down 0.99% at $100.75 during the premarket session on the last check Thursday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.